Sarepta Therapeutics Inc (SRPT) - Total Assets
Based on the latest financial reports, Sarepta Therapeutics Inc (SRPT) holds total assets worth $3.49 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Sarepta Therapeutics Inc for net asset value and shareholders' equity analysis.
Sarepta Therapeutics Inc - Total Assets Trend (1995–2024)
This chart illustrates how Sarepta Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Sarepta Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Sarepta Therapeutics Inc's total assets of $3.49 Billion consist of 77.6% current assets and 22.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.8% |
| Accounts Receivable | $649.73 Million | 16.4% |
| Inventory | $749.96 Million | 18.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $26.89 Million | 0.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2024)
This chart illustrates how Sarepta Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sarepta Therapeutics Inc (SRPT) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sarepta Therapeutics Inc's current assets represent 77.6% of total assets in 2024, an increase from 39.1% in 1995.
- Cash Position: Cash and equivalents constituted 27.8% of total assets in 2024, down from 30.4% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 17.0% in 1995.
- Asset Diversification: The largest asset category is inventory at 18.9% of total assets.
Sarepta Therapeutics Inc Competitors by Total Assets
Key competitors of Sarepta Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Sarepta Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.95 | 3.84 | 5.97 |
| Quick Ratio | 1.79 | 3.03 | 5.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.80 Billion | $1.99 Billion | $2.07 Billion |
Sarepta Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Sarepta Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.41 |
| Latest Market Cap to Assets Ratio | 0.47 |
| Asset Growth Rate (YoY) | 21.4% |
| Total Assets | $3.96 Billion |
| Market Capitalization | $1.86 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sarepta Therapeutics Inc's assets below their book value (0.47x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sarepta Therapeutics Inc's assets grew by 21.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sarepta Therapeutics Inc (1995–2024)
The table below shows the annual total assets of Sarepta Therapeutics Inc from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.96 Billion | +21.40% |
| 2023-12-31 | $3.26 Billion | +4.35% |
| 2022-12-31 | $3.13 Billion | -0.62% |
| 2021-12-31 | $3.15 Billion | +5.47% |
| 2020-12-31 | $2.98 Billion | +63.74% |
| 2019-12-31 | $1.82 Billion | +11.01% |
| 2018-12-31 | $1.64 Billion | +25.54% |
| 2017-12-31 | $1.31 Billion | +208.41% |
| 2016-12-31 | $424.10 Million | +54.91% |
| 2015-12-31 | $273.78 Million | -7.20% |
| 2014-12-31 | $295.03 Million | +1.19% |
| 2013-12-31 | $291.57 Million | +42.23% |
| 2012-12-31 | $204.99 Million | +277.05% |
| 2011-12-31 | $54.37 Million | +18.25% |
| 2010-12-31 | $45.98 Million | -23.41% |
| 2009-12-31 | $60.03 Million | +135.07% |
| 2008-12-31 | $25.54 Million | -33.91% |
| 2007-12-31 | $38.64 Million | -5.44% |
| 2006-12-31 | $40.86 Million | -27.56% |
| 2005-12-31 | $56.41 Million | +97.79% |
| 2004-12-31 | $28.52 Million | -39.51% |
| 2003-12-31 | $47.15 Million | +64.82% |
| 2002-12-31 | $28.60 Million | -15.41% |
| 2001-12-31 | $33.82 Million | -3.63% |
| 2000-12-31 | $35.09 Million | +172.00% |
| 1999-12-31 | $12.90 Million | +26.47% |
| 1998-12-31 | $10.20 Million | -45.74% |
| 1997-12-31 | $18.80 Million | +347.62% |
| 1996-12-31 | $4.20 Million | +82.61% |
| 1995-12-31 | $2.30 Million | -- |
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exo… Read more